A Phase 4 interventional study of Anaferon for children and Placebo in Preventive Medicine, sponsored by Materia Medica Holding. Completed at 33 sites in 2 countries. Open to participants aged 1 Month to 6 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-05-06.
Sponsored by Materia Medica Holding · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to obtain additional data on the efficacy and safety of 12-week course of therapy with Anaferon for children for prevention of influenza and other acute respiratory viral infections in children during the peaks of seasonal morbidity.
Design: an international, multicenter, double-blind, placebo-controlled, randomized study in parallel groups.
The study will enroll children of either gender aged of 1 month to 6 years old. Children can participate in the study, regardless of the frequency of previous ARVI. A potential study participant should not be in the incubation (if known), prodromal, acute/subacute periods of any infectious disease (except for the recovery period). Schedule for enrollment of participants: during the period of a seasonal rise in influenza/ARVI incidence in the Russian Federation and the Republic of Uzbekistan. Screening and randomization of participants will be subject to availability of official information on the incidence of influenza/ARVI in the relevant study region.
The doctor makes the first visit to the participant in the medical center or at home. After the parent/adoptive parent signs the information sheet (informed consent form), the doctor evaluates the possibility of the participant being included in the trial. If the child meets all the inclusion criteria and does not have all non-inclusion criteria, then he/she is included in the study, the doctor fills in Clinical Research Form. At visit 1 (Day 1), the participant is randomized into one of two groups: the 1st group participants will take Anaferon for children according to the preventive regimen for 12 weeks; the 2nd group participants will take Placebo according to the regimen of Anaferon for 12 weeks.
In total, the study participant will be observed for 12 weeks (screening and randomization up to 1 day, preventive treatment for 12 weeks).
During the observation period at 4 (Visit 2), 8 (Visit 3) and 12 (Visit 4) weeks, three visits are planned.
Visits 2 (Week 4 ± 3 days) and 3 (Week 8 ± 3 days) are conducted in the form of a telephone survey of parents/adoptive parents about the participant's health status, presence/absence of symptoms of influenza/ARVI, possible use of antibacterial drugs and/or hospitalization during the course preventive therapy.
Visit 4 (Week 12 ± 3 days) is carried out at home or in a medical center; the doctor collects complaints, examines the participant, registers concomitant therapy, assesses the compliance of the therapy.
If in the period from 2 to 12 weeks a participant falls ill with influenza/ARVI, then he/she prematurely completes participation in the study (as having reached the primary endpoint). A participant is considered fallen ill with influenza/ARVI if the doctor identifies the following symptoms: febrile/subfebrile body temperature, presence at least one flu-like nonspecific symptom (decreased activity/impaired behavior/weakness; headache; chills) and at least one respiratory symptom (runny nose; nasal stuffiness; hoarseness/husky voice; sore throat; cough). In this case, the doctor makes an unscheduled visit (at home or in a medical center), which is final. During the visit, the doctor carries out the procedures of Visit 4. A nasopharyngeal swab is taken to identify the most common pathogens of influenza/ARVI.
If ARVI/influenza occurs within the first seven days from the onset of preventive therapy, the disease will not be recorded as an adverse event and will not be taken into account to evaluate the efficacy of the study drug, since an early manifestation of influenza/ARVI may indicate that the participant was included in the study when he/she was in the incubation period of an infectious disease.
During the study, concomitant therapy for underlying chronic conditions, as well as routine vaccination of the participant, are allowed, with the exception of the drugs indicated in the section "Prohibited Concomitant Treatment".
Materia Medica Holding is the lead sponsor of 43 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History of (verified previously) or current suspected conditions such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tablet for oral use. One tablet per intake, once daily (approximately at the same time). The product is administered outside a meal (in the interval between meals or 15 min prior to meal or fluid intake), the tablets should be held in mouth until complete dissolution. For young children (aged 1 month to 3 years old), the tablet is recommended to be dissolved in a small amount (1 tablespoon) of drinking water of room temperature.
Drug: Anaferon for children
Tablet for oral use. Placebo using Anaferon for children scheme.
Drug: Placebo
Tablet for oral use.
Tablet for oral use.
Time From Taking the First Dose of the Study Drug to the Onset of Influenza/ARVI Symptoms.
Based on medical records.
Time frame: in 12 weeks of the treatment
Percentage of Children Not Falling Ill With Influenza or Another ARVI.
Based on medical records. Influenza/ARVI criteria are the following: febrile/subfebrile body temperature, presence at least one flu-like nonspecific symptom (decreased activity/weakness, headache, and chills), and at least one respiratory symptom (runny nose, nasal stuffiness, hoarseness/husky voice, sore throat, and cough).
Time frame: in 12 weeks of the treatment
Percentage of Children With the Symptoms Requiring Antibacterial Therapy.
Based on medical records. Percentage of children with the symptoms of a respiratory or ear-nose-throat bacterial infection requiring antibacterial therapy.
Time frame: in 12 weeks of the treatment
Percentage of Children Requiring Hospitalized for Influenza/ARVI.
Based on medical records. Percentage of children hospitalized for influenza/ARVI or their complications.
Time frame: in 12 weeks of the treatment
Presence and Type of Adverse Events (AE).
Based on medical records. Presence and type of adverse events, their severity, relation to investigational drug, outcomes.
Time frame: in 12 weeks of the treatment
| Milestone | Anaferon for Children | Placebo |
|---|---|---|
| Started | 528 | 508 |
| Completed | 520 | 501 |
| Not completed | 8 | 7 |
| Withdrew: Сompliance with exclusion criteria | 8 | 7 |
Based on medical records.
| days | Anaferon for Children | Placebo |
|---|---|---|
| Time From Taking the First Dose of the Study Drug to the Onset of Influenza/ARVI Symptoms. | 428.8 (351.0 to 523.8) | 275.8 (232.7 to 326.9) |
Based on medical records. Influenza/ARVI criteria are the following: febrile/subfebrile body temperature, presence at least one flu-like nonspecific symptom (decreased activity/weakness, headache, and chills), and at least one respiratory symptom (runny nose, nasal stuffiness, hoarseness/husky voice, sore throat, and cough).
| Participants | Anaferon for Children | Placebo |
|---|---|---|
| 4 weeks | 516 | 452 |
| 8 weeks | 482 | 415 |
| 12 weeks | 424 | 368 |
Based on medical records. Percentage of children with the symptoms of a respiratory or ear-nose-throat bacterial infection requiring antibacterial therapy.
| Participants | Anaferon for Children | Placebo |
|---|---|---|
| Percentage of Children With the Symptoms Requiring Antibacterial Therapy. | 3 | 8 |
Based on medical records. Percentage of children hospitalized for influenza/ARVI or their complications.
| Participants | Anaferon for Children | Placebo |
|---|---|---|
| Percentage of Children Requiring Hospitalized for Influenza/ARVI. | 0 | 0 |
Based on medical records. Presence and type of adverse events, their severity, relation to investigational drug, outcomes.
| Participants | Anaferon for Children | Placebo |
|---|---|---|
| Mild severity | 65 | 54 |
| Moderate severity | 4 | 4 |
Collected over Adverse/Serious adverse events were registered during 12 weeks therapy.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Anaferon for Children | 0/528 (0%) | 1/528 (0.2%) | 49/528 (9.3%) |
| Placebo | 0/508 (0%) | 0/508 (0%) | 44/508 (8.7%) |
| Event | Anaferon for Children | Placebo |
|---|---|---|
| Partial crampsNervous system disorders | 1/528 | 0/508 |
| Event | Anaferon for Children | Placebo |
|---|---|---|
| Chicken poxInfections and infestations | 4/528 | 8/508 |
| FeverGeneral disorders | 7/528 | 0/508 |
| Acute nasopharyngitisInfections and infestations | 6/528 | 3/508 |
| Runny noseRespiratory, thoracic and mediastinal disorders | 6/528 | 2/508 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 5/528 | 2/508 |
| Respiratory viral infectionInfections and infestations | 3/528 | 4/508 |
| Acute respiratory tract infectionInfections and infestations | 4/528 | 4/508 |
| Allergic rashSkin and subcutaneous tissue disorders | 0/528 | 3/508 |
| TeethingGastrointestinal disorders | 3/528 | 1/508 |
| Functional gastrointestinal pathologyGastrointestinal disorders | 3/528 | 1/508 |
| Age, Categorical(Participants) | Anaferon for Children | Placebo | Total |
|---|---|---|---|
| <=18 years | 520 | 501 | 1021 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Anaferon for Children | Placebo | Total |
|---|---|---|---|
| Mean | 3.1 ± 1.7 | 3.1 ± 1.7 | 3.1 ± 1.7 |
| Sex: Female, Male(Participants) | Anaferon for Children | Placebo | Total |
|---|---|---|---|
| Female | 263 | 244 | 507 |
| Male | 257 | 257 | 514 |
| Race and Ethnicity Not Collected(Participants) | Anaferon for Children | Placebo | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Anaferon for Children | Placebo | Total |
|---|---|---|---|
| Uzbekistan | 15 | 15 | 30 |
| Russia | 505 | 486 | 991 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2017 to primary completion in May 2019, 19 months.
Results were first posted in May 2020, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.